The Effects of Trimetazidine on QT-interval Prolongation and Cardiac Hypertrophy in Diabetic Rats

Abstract Background: Trimetazidine (TMZ) is an anti-ischemic drug. In spite of its protective effects on cardiovascular system, there is no scientific study on the usefulness of TMZ treatment for prolonged QT interval and cardiac hypertrophy induced by diabetes. Objectives: To evaluate the effects of TMZ on QT interval prolongation and cardiac hypertrophy in the diabetic rats. Methods: Twenty-four male Sprague-Dawley rats (200-250 g) were randomly assigned into three groups (n = 8) by simple random sampling method. Control (C), diabetic (D), and diabetic administrated with TMZ at 10 mg/kg (T10). TMZ was administrated for 8 weeks. The echocardiogram was recorded before isolating the hearts and transfer to a Langendorff apparatus. Hemodynamic parameters, QT and corrected QT interval (QTc) intervals, heart rate and antioxidant enzymes were measured. The hypertrophy index was calculated. The results were evaluated by one-way ANOVA and paired t-test using SPSS (version 16) and p背景：曲美他嗪（Trimetazidine，TMZ）是一种抗缺血药物。尽管其对心血管系统具有保护作用，但目前尚无科学研究探讨曲美他嗪治疗糖尿病诱导的QT间期延长与心肌肥厚的有效性。研究目的：评估曲美他嗪对糖尿病大鼠QT间期延长及心肌肥厚的影响。实验方法：将24只体重200~250g的雄性Sprague-Dawley（SD）大鼠采用简单随机抽样法随机分为3组，每组8只，分别为对照组（C）、糖尿病模型组（D）以及以10mg/kg剂量给予曲美他嗪的糖尿病给药组（T10）。给药持续8周。在分离心脏并转移至朗德多夫灌流装置（Langendorff apparatus）前，记录超声心动图。随后测定血流动力学参数、QT间期及校正QT间期（QTc）、心率与抗氧化酶活性，并计算肥厚指数。实验数据采用SPSS（版本16）软件进行单因素方差分析（one-way ANOVA）及配对t检验，p